Corcept's Relacorilant Faces FDA Decision, Stock Volatility

Markets & Money Today | 2 Min News | The Daily News Now! - A podcast by The Daily News Now! - Tuesdays

Podcast artwork

Categories:

Business

Corcept Therapeutics stock drops 4.7% as investors await FDA decision on drug candidate relacorilant, with mixed trial results and analysts cautious outlook.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.